EB Research Funding 2022 - Calls for Proposals opening soon

EB Resnet is a network of Epidermolysis Bullosa (EB) patient organisations funding promising EB research worldwide and partnering with the industry, academics, clinicians and other funders to drive its translation to clinical benefit. Our mission is to support the development of efficacious, safe and affordable medicines for people living with EB.

EB Resnet is now inviting research proposals for the ‘All-Priorities’ Research Call 2022 and the special Ad-hoc Call ‘Repurposing Drugs for EB’ 2022.

 

All Priorities Call 2022

There is a one-stage application process with an opening on Wednesday, June 01, 2022.
This grant’s scheme calls for research proposals across our four priority research areas:

• Improving understanding of EB biology to create new concepts for diganosis and treatment.
• Developing disease-modifying and curative therapies.
• Preventing and curing severe disease consequences: chronic wounds, fibrosis, and cancer.
• Improving clinical care and symptom-relief through research.

EB Resnet offers to fund individual research projects up to EUR 270,000 over three years.

The closing date for applications is Tuesday, September 06, 2022, at 15:00 GMT.
For further information, please visit this link.

 

Special Ad-Hoc Call ‘Repurposing drugs for EB’ 2022

In addition to the ‘All Priorities’ Research Call 2022, this year EB Resnet has agreed to provide an additional funding stream to support proof-of-concept projects aimed at exploring possible repurposing opportunities that tackle the following EB’s unmet medical needs:

• Chronic inflammation and fibrosis
• Pain
• Itch
• Cutaneous squamous cell carcinoma (cSCC)

Funding will prioritise molecules under patent or generic drugs undergoing clinical or late-preclinical testing supported by strong safety and efficacy data in indications where targeted pathways provide a robust rationale for their exploration in the context of EB.

We welcome applications from the industry, academic researchers, or mixed consortia. We offer to fund individual research projects up to EUR 40,000 over 3-6 months (funding awarded will be proportionate to the narrow study requirements). Co-funding opportunities are available.

There is a one-stage application process with an opening on Wednesday, June 01, 2022.

Peer-reviewed applications will be prioritized for funding according to their scientific quality, robustness of preliminary pre-clinical and/or clinical data suggesting possible benefit for EB patients, feasibility, and potential for being translated into the clinic.  

EB Resnet anticipates holding a follow-on Call for larger-scale projects and possible clinical trials on the same theme in 2023; in some cases, the current special Ad-hoc Call is expected to enable researchers to build the foundations for applications to the 2023 Call.

The closing date for applications is Tuesday, September 06, 2022, at 15:00 GMT.

For further information, please visit this link.